Rating Change
RBC Capital reiterated its Outperform rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on October 08, 2026.
reiterateNASDAQ:ALNY
RBC Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals, Inc. (ALNY)
RBC Capital reiterated its Outperform rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on October 08, 2026.
At publication ·
What changed
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) · reiterate
- Firm
- RBC Capital
- Rating
- Outperform to Outperform
- Price at event
- $219.97
- Market capitalization
- $44.2B
At a glance
Key takeaways
- RBC Capital maintained an Outperform rating on Alnylam Pharmaceuticals (ALNY) on October 8, 2026.
Market Context
Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $219.97 with a market capitalization of $44.2B. The stock has declined 50.4% over the past 52 weeks.
Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Alnylam Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Alnylam Pharmaceuticals, Inc.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 08, 2026 | RBC Capital | Outperform | N/A |
| Sep 30, 2026 | JP Morgan | Overweight | N/A |
| Sep 21, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 08, 2026 | Jefferies | Hold | N/A |
| Sep 02, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ALNY Stock Page
Frequently Asked Questions
What does the Outperform rating mean for ALNY?
A rating of Outperform from RBC Capital reflects the analyst's outlook on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ALNY forecast page.